Valeant Pharma (VRX) Reports Q3 EPS of $3.69, Beating Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant Announces Third-Quarter 2017 Results
November 7, 2017 7:01 AM ESTLAVAL, Quebec, Nov. 7, 2017 /PRNewswire/ --
Strong Third-Quarter 2017 Financial Results Revenues of $2,219 million GAAP Net Income of $1,301 million Adjusted Net Income (non-GAAP) of $367 million GAAP Cash Flow From Operations of $490 million; Year-to-Date of $1,712 million Adjusted EBITDA (non-GAAP) of $951 million Delivered Strong Organic Growth1 (non-GAAP) in Bausch + Lomb/International Segment and Salix Business Exceeds $5 Billion Debt Reduction Commitment Early Updates 2017 Full-Year Revenue and Maintains Adjusted EBITDA (non-GAAP) Guidance Range Despite Asset DivestituresValeant... More
